Drug data last refreshed 17h ago · AI intelligence enriched 2w ago
INFED (iron dextran) is an injectable iron replacement therapy administered intravenously or intramuscularly to treat iron deficiency anemia. It replenishes depleted iron stores by delivering a dextran-iron complex that is taken up by the reticuloendothelial system and incorporated into hemoglobin. This small molecule is indicated for patients who cannot tolerate or absorb oral iron supplementation.
Product approaching loss of exclusivity with moderate competitive pressure (30); teams are likely focused on lifecycle management and cost optimization rather than expansion.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Intravaneous Iron(1000 mg Low Molecular Weight Iron Dextran Over 60 Minutes) for Pregnant Women
Working on INFED offers limited career growth opportunity given its LOE-approaching lifecycle and lack of active clinical pipeline. Roles focus on legacy brand management, pricing defense, and transition planning rather than launching innovation or entering new markets.
Worked on INFED at AbbVie? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo